Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Sarepta Therapeutics Inc Market Cap
Based on ratings from 18 stock analysts, the Sarepta Therapeutics Inc stock price is expected to increase by 50.97% in 12 months. This is calculated by using the average 12-month stock price forecast for Sarepta Therapeutics Inc. The lowest target is $110 and the highest is $220. Please note analyst price targets are not guaranteed and could be missed completely.
SRPT is a stock in Health Care which has been forecasted to be worth $188.73 as an average. On the higher end, the forecast price is $220 USD by from RBC Capital and on the lower end SRPT is forecasted to be $110 by from .
These are the latest 20 analyst ratings of SRPT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brian Abrahams RBC Capital | Outperform | $181 | Reiterates | Sep 6, 2024 |
| Brian Abrahams RBC Capital | Outperform | $181 | Reiterates | Aug 15, 2024 |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $179 | Upgrade | Aug 8, 2024 |
| David Hoang Citigroup | Neutral | $160 | Maintains | Aug 8, 2024 |
| Brian Abrahams RBC Capital | Outperform | $181 | Maintains | Aug 8, 2024 |
| Gena Wang Barclays | Overweight | $203 | Maintains | Aug 8, 2024 |
| Biren Amin Piper Sandler | Overweight | $200 | Maintains | Aug 8, 2024 |
| Kristen Kluska Cantor Fitzgerald | Neutral | $152 | Maintains | Aug 8, 2024 |
| Brian Abrahams RBC Capital | Outperform | $182 | Upgrade | Jul 29, 2024 |
| Biren Amin Piper Sandler | Overweight | $205 | Maintains | Jul 1, 2024 |
| Gil Blum Needham | Buy | $235 | Reiterates | Jun 27, 2024 |
| David Hoang Citigroup | Neutral | $176 | Downgrade | Jun 26, 2024 |
| Gavin Clark-Gartner Evercore ISI Group | In-Line | $185 | Maintains | Jun 24, 2024 |
| Matthew Harrison Morgan Stanley | Overweight | $200 | Maintains | Jun 24, 2024 |
| Mani Foroohar Leerink Partners | Outperform | $230 | Maintains | Jun 24, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $200 | Maintains | Jun 24, 2024 |
| Gena Wang Barclays | Overweight | $226 | Maintains | Jun 21, 2024 |
| Kristen Kluska Cantor Fitzgerald | Neutral | $128 | Reiterates | Jun 21, 2024 |
| Brian Skorney Baird | Outperform | $200 | Maintains | Jun 21, 2024 |
| Matthew Harrison Morgan Stanley | Overweight | $165 | Reiterates | Jun 21, 2024 |
When did it IPO
N/A
Staff Count
1,314
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Douglas S. Ingram Esq.
Market Cap
$11.99B
In 2023, SRPT generated $1.24B in revenue, which was a increase of 33.26% from the previous year. This can be seen as a signal that SRPT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Sarepta Therapeutics appointed Deirdre P. Connelly to its Board of Directors, expanding it to nine members, with eight being independent. Connelly brings over 30 years of pharmaceutical experience.
Why It Matters - Deirdre P. Connelly's appointment to Sarepta's Board adds experienced leadership, potentially enhancing strategic decisions and boosting investor confidence in the company's future.
Fri, 13 Sep 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Viking Therapeutics is nearing the launch of a potentially multibillion-dollar weight loss product, while Sarepta Therapeutics advances treatments for rare diseases.
Why It Matters - Viking Therapeutics' weight loss product could significantly boost revenue, while Sarepta Therapeutics targets a niche market, potentially increasing its valuation and attracting investment interest.
Fri, 06 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Sarepta Therapeutics (SRPT) reported earnings 30 days ago; investors should monitor upcoming developments for potential stock movements.
Why It Matters - Sarepta's earnings report can indicate its financial health and future growth potential, impacting stock performance and investor sentiment.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Sarepta Therapeutics announced 25 recipients of its Duchenne Scholarship Program for 2024-2025, providing scholarships up to $5,000 to individuals with Duchenne muscular dystrophy and their siblings.
Why It Matters - Sarepta's scholarship program enhances its reputation in the rare disease community, potentially boosting brand loyalty and long-term value among patients and families, impacting future sales.
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Sarepta Therapeutics granted equity awards to 20 new employees on August 30, 2024, under its 2024 Employment Commencement Incentive Plan, approved by its Compensation Committee.
Why It Matters - Sarepta's equity awards to new hires may indicate growth and expansion, potentially impacting future performance and stock value, which is crucial for investor decisions.
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Sarepta Therapeutics will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Sept. 6, 2024, at 9:15 a.m. ET, with a live webcast available.
Why It Matters - Sarepta's participation in a major healthcare conference may signal upcoming developments or insights into its pipeline, influencing investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
